Zoar files Form F-4 for Impact Biomedical business combination
DSS said Zoar filed a preliminary Form F-4 with the SEC for Impact Biomedical’s proposed business combination with Zoar, subject to SEC review and other closing conditions.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.